NICE won't endorse NHS coverage of Bristol's RA drug Orencia

03/29/2011 | Wall Street Journal, The

The U.K. National Institute for Health and Clinical Excellence said Bristol-Myers Squibb's Orencia, or abatacept, is not cost-effective for National Health Service use as second-line treatment for adults with moderate to severe rheumatoid arthritis who did not respond to standard nonbiologic medicines. The agency said it already endorsed coverage of several other RA drugs.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN